The launch status of talazoparib in China in 2024 and the latest information on medical insurance

Talazoparib, as an innovativePARP inhibitor, has attracted much attention in the field of cancer treatment. It effectively blocks DNA damage repair by precisely inhibiting the activity of poly-ADP-ribose polymerase, thereby promoting the apoptosis of tumor cells. However, despite its remarkable efficacy, talazoparib has not yet been approved by the China Food and Drug Administration, and domestic patients cannot yet purchase it directly from pharmacies.

The inclusion of drugs in medical insurance is usually based on whether the drug has been approved by the China Food and Drug Administration. Therefore, at this stage, talazoparib is not covered by medical insurance. This is undoubtedly a big challenge for patients who need this drug. However, for patients who urgently need medicine, they can choose to purchase it from overseas regular channels, but they must pay attention to ensure the quality and safety of the medicine.

The original drug of talazoparib produced by Pfizer currently has two main specifications, namely0.25mg*30 tablets and 1mg*30 tablets. Despite its remarkable efficacy, the high price prohibits many patients. A box of 0.25mg*30 pills sells for more than RMB 10,000 per box, while a box of 1mg*30 pills costs nearly RMB 50,000. This is undoubtedly a heavy burden for patients with greater financial pressure.

In this context, the emergence of generic drugs provides patients with new treatment options. The generic version of talazoparib produced by Laos Element Pharmaceuticals is affordable. A box of 1mg*30 pills sells for about 4,000 yuan, which is only about one-tenth of the original drug. This price advantage gives many patients hope of treatment.

In general, although talazoparib has not yet been marketed and included in medical insurance in China, patients can still obtain the drug through other channels. At the same time, the emergence of generic drugs has also provided patients with more treatment options. In the future, we hope that talazoparib will be approved by the China Food and Drug Administration as soon as possible so that more patients can benefit from it.